Ep 16: MASTERKEY 265

Summary

James gives a response of plausible deniability that hints at activities as a spy for MI6. But is Sapna perhaps the optimal agent for the clandestine services?

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the intricacies of the MASTERKEY 265 study, focusing on the combination of TVEC and pembrolizumab in melanoma treatment. They explore the study's design, patient demographics, and the implications of geographical variations on trial outcomes. The conversation highlights the importance of understanding patient selection and trial design in oncology, as well as the lessons learned from the study's overall negative results.

Keywords

TVEC, Master Key 265, melanoma, immunotherapy, clinical trials, patient demographics, efficacy, safety, geographical variations, oncology

Takeaways

The Master Key 265 study had dual primary endpoints of PFS and OS.

TVEC was combined with Pembrolizumab in the study.

The phase 1B trial showed significant efficacy but the phase 3 trial was negative.

Patient demographics can greatly influence trial outcomes.

Geographical variations can lead to different efficacy results.

Toxicity levels were similar between the treatment arms.

The study design must consider patient selection carefully.

The Optim study had different eligibility criteria than Master Key 265.

Understanding baseline characteristics is crucial for interpreting trial results.

Future trials should learn from the design of Master Key 265.

Titles

Lessons Learned from Master Key 265

The Role of Trial Design in Oncology

Sound Bites

"This was an interesting study because it was a phase 1B."

"The toxicity between the two arms was really exceptionally similar."

Chapters

00:00 Combining Intratumoral Therapies with Checkpoint Inhibitors

04:51 Master Key 265 Study: TVEC and Pembrolizumab Combination

09:42 Primary Endpoint: Progression-Free Survival

11:44 Importance of Durable Response Rate as an Endpoint

13:37 Limited Activity of TVEC and Pembrolizumab Combination

14:52 Geographical Variation in Treatment Outcomes